恩替卡韦治疗48周后血清HBeAg、HBsAg定量与HBV-DNA变化的相关性

陈邦银; 黄津

文章摘要

陈邦银黄津.恩替卡韦治疗48周后血清HBeAg、HBsAg定量与HBV-DNA变化的相关性[J].实用中西医结合临床,2015,15(4):4-5，44

恩替卡韦治疗48周后血清HBeAg、HBsAg定量与HBV-DNA变化的相关性

Correlation of the Quantitative Change of Serum HBeAg, HBsAg and HBV-DNA after 48 Weeks’ Entecavir Therapy

DOI：

中文关键词: 乙型肝炎恩替卡韦肝炎e抗原

英文关键词: Hepatitis B Entecavir HBeAg

基金项目:

作者	单位
陈邦银黄津	福建医科大学附属南平第一医院感染科

摘要点击次数: 856

全文下载次数: 458

中文摘要:

目的：观察恩替卡韦治疗HBeAg阳性慢性乙型肝炎48周后乙肝病毒血清标志物含量与HBV-DNA含量的关系。方法：选取2011年3月~2013年6月期间于本院就诊的HBeAg阳性慢性乙型肝炎患者58例，给予恩替卡韦0.5 mg口服，1次/d，随访48周。结果：经过48周恩替卡韦治疗后ALT复常率77.59%，HBV-DNA转阴率72.41%，HBeAg转阴率39.66%，HBeAg血清转换率27.59%。治疗过程中HBeAg、HBV-DNA定量值均呈下降趋势，随着治疗时间的延长，HBeAg、HBV-DNA定量值持续下降，两者之间存在显著的正相关性，且具有统计学意义（R=0.801，P＜0.05）；但HBsAg定量与血清HBeAg、HBV-DNA变化水平之间无显著关系（P＞0.05）。结论：恩替卡韦有明显抑制血清HBV-DNA复制和提高HBeAg血清学转换的作用，HBeAg基线水平可以预测恩替卡韦治疗HBeAg阳性慢性乙肝患者的HBeAg血清学转换率。HBeAg含量变化与HBV-DNA含量变化存在显著的正相关性，HBsAg含量变化与HBV-DNA含量变化无明显相关性。

英文摘要:

Objective: To investigate the relationship of serum markers of hepatitis B virus and HBV-DNA contents after 48 weeks’ entecavir therapy in the treatment of HBeAg positive chronic hepatitis B. Methods: From March 2011 to June 2013, 58 patients of HBeAg positive chronic hepatitis B in our hospital were given the entecavir (0.5 mg/d) orally, and they were followed up for 48 weeks. Results: After 48 weeks of treatment, the recovery rate of ALT was 77.59%, the negative conversion rate of HBV-DNA was 72.41%, the negative conversion rate of HBeAg was 39.66%, and the seroconversion rate of HBeAg was 27.59%. In the course of treatment, HBeAg and HBV-DNA quantitative value decreased, and with the extension of treatment time, HBeAg and HBV-DNA quantitative value continued to decline. Obviously, there was a significant positive correlation between the two factors and it showed statistical significance (R=0.801, P<0.05); but there was no significant relationship between HBsAg quantitative and serum HBeAg, HBV-DNA levels (P>0.05). Conclusion: Entecavir can inhibit the replication of HBeAg and increase serum HBV-DNA serological conversion function; and the baseline of HBeAg levels can predict HBeAg seroconversion rate of HBeAg positive chronic hepatitis B patients in the treatment of entecavir. Changes of HBV-DNA content and HBeAg content show a significant positive correlation, and there is no significant correlation between changes in HBV-DNA content and HBsAg content.

查看全文查看/发表评论下载PDF阅读器

关闭